Correspondence 0001213900-23-052008 from INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC.
Date: June 27, 2023 · CIK: 0001567264 · Accession: 0001213900-23-052008
AI Filing Summary & Sentiment
File numbers found in text: 333-260565
Letter
Re: Intensity Therapeutics, Inc.
June 27, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-260565
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representative of the several underwriters, hereby join in the request of Intensity Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 PM, Eastern Time, on June 29, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, McDermott Will & Emery LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Acting severally on behalf of itself and the several underwriters
Show Raw Text
CORRESP
1
filename1.htm
June 27, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Intensity Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-260565
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended (the “Act”), we, as representative of the several underwriters, hereby join in the request
of Intensity Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration
Statement so that it becomes effective at 4:30 PM, Eastern Time, on June 29, 2023, or as soon thereafter as practicable, or at such other
time as the Company or its outside counsel, McDermott Will & Emery LLP, request by telephone that such Registration Statement be declared
effective.
Pursuant to Rule 460 under the Act, please be advised
that we will take reasonable steps to secure adequate distribution of the prospectus to underwriters, dealers, institutions and others
prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the
several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied
and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Acting severally on behalf of itself and the several underwriters
THE BENCHMARK COMPANY, LLC
By:
/s/ Michael S. Jacobs
Name:
Michael S. Jacobs
Title:
Managing Director